Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular Sponsors: Qianfoshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: PD-1 monoclonal antibody; Drug: targeted drugs Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: Targeted drugs; Drug: PD-1 monoclonal antibody Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
Conditions: Endometrial Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
Conditions: Bladder Cancer Interventions: Drug: Tislelizumab combined with two predefined dose groups of palbociclib; Drug: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial. Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
An Phase III Study, Multicenter ，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Conditions: Bladder Cancer Interventions: Drug: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib; Drug: Tislelizumab, Cisplatin, Gemcitabine Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Radical Synchronous Chemoradiotherapy With DDP/5-FU and PD-1 for Non-metastatic Rectal Squamous Cell Carcinoma
Conditions: Rectal Squamous Cell Carcinoma Interventions: Combination Product: PD-1 and CRT Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
CARE1 Pragmatic Clinical Trial
Conditions: Metastatic Kidney Cancer; Metastatic Kidney Carcinoma Interventions: Drug: Nivolumab; Drug: Ipilimumab; Drug: Pembrolizumab; Drug: Cabozantinib; Drug: Axitinib; Drug: Lenvatinib Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; European Commission; CRIS Cancer Foundation; National Cancer Institute, France; Rennes University Hospital; University Hospital, Essen; Fundaci ó Privada Institut d ' Investigaci ó Oncològica de Vall d ' Hebron; The Netherlands Cancer Institute; Servicio Madrile ño de Salud, Madrid, Spain; Hospital Universitario 12 de Octubre; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan...
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases
Conditions: Hepatocellular Carcinoma, Non-cirrhotic Liver Interventions: Other Sponsors: Xiao Xu Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma
Conditions: Time Interventions: Radiation: Neoadjuvant chemradiotherapy; Procedure: Minimally invasive esophagectomy Sponsors: Shanghai Zhongshan Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma Interventions: Drug: Sintilimab, bevacizumab, gemcitabine; Radiation: IMRT Sponsors: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC
Conditions: Carcinoma; Small Cell Lung Cancer Interventions: Procedure: Drug-eluting beads bronchial arterial chemoembolization; Drug: Serplulimab; Procedure: Intravenous chemotherapy Sponsors: The Central Hospital of Lishui City Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Conditions: Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Gastric Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Gastric Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Unresectable Gastric Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma; Unresectable Malignant Solid Neoplasm Interventions...
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
Conditions: Advanced Solid Tumor; Carcinomatosis Interventions: Drug: VG2025 Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: HAIC+STRIDE+Len Sponsors: Sulai Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
